Adicet Bio Inc(ACET-Q)NASDAQ
Today's Change
Real-Time Last Update
After Hours Change
After Hours Last Update
Volume
Latest News
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Business Wire - Fri Apr 28, 2023
Business Wire
Fri Apr 28, 2023
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced it granted inducement awards on April 28, 2023.
Adicet Bio to Participate in 2023 Canaccord Genuity Horizons in Oncology Virtual Conference
Business Wire - Thu Apr 13, 2023
Business Wire
Thu Apr 13, 2023
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that Chen Schor, President and Chief Executive Officer will participate in a...
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Business Wire - Fri Mar 31, 2023
Business Wire
Fri Mar 31, 2023
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced it granted inducement awards on March 31, 2023.
Adicet Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Company Progress
Business Wire - Wed Mar 15, 2023
Business Wire
Wed Mar 15, 2023
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today reported financial results and operational highlights for the fourth quarter and year...
Adicet Bio to Participate in 2023 Jefferies Biotech on the Bay Summit
Business Wire - Thu Mar 9, 2023
Business Wire
Thu Mar 9, 2023
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that Chen Schor, President and Chief Executive Officer, and Nick Harvey, Chief...
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Business Wire - Tue Feb 28, 2023
Business Wire
Tue Feb 28, 2023
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced it granted inducement awards on February 28, 2023.
Adicet Bio to Participate in a Fireside Chat at the 2023 Guggenheim Oncology Conference
Business Wire - Wed Feb 1, 2023
Business Wire
Wed Feb 1, 2023
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a...
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Business Wire - Tue Jan 31, 2023
Business Wire
Tue Jan 31, 2023
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced it granted inducement awards on January 31, 2023.
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Business Wire - Fri Dec 30, 2022
Business Wire
Fri Dec 30, 2022
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced it granted inducement awards on December 30, 2022.
Adicet Bio Reports Positive Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)
Business Wire - Sat Dec 10, 2022
Business Wire
Sat Dec 10, 2022
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced positive safety and efficacy data from the Company’s ongoing Phase 1 study of...
Adicet Bio to Host Investor Webcast to Discuss Updated Clinical Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)
Business Wire - Fri Dec 2, 2022
Business Wire
Fri Dec 2, 2022
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that the Company will host a webcast presentation on Sunday, December 11, 2022...
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Business Wire - Wed Nov 30, 2022
Business Wire
Wed Nov 30, 2022
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced it granted inducement awards on November 30, 2022.
Adicet Bio to Present at the Virtual JMP Securities Hematology and Oncology Summit
Business Wire - Wed Nov 30, 2022
Business Wire
Wed Nov 30, 2022
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that Chen Schor, President and Chief Executive Officer, will present at the...
Adicet Bio Appoints Nancy Boman, M.D., Ph.D., as Senior Vice President and Chief Regulatory Officer
Business Wire - Tue Nov 29, 2022
Business Wire
Tue Nov 29, 2022
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced the appointment of Nancy Boman, M.D., Ph.D., as Senior Vice President and Chief...
Adicet Reports Third Quarter 2022 Financial Results and Provides Business Updates
Business Wire - Tue Nov 8, 2022
Business Wire
Tue Nov 8, 2022
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today reported financial results and operational highlights for the third quarter ended...
Adicet Bio Showcases Preclinical Data for Four New Pipeline Programs at The Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
Business Wire - Mon Nov 7, 2022
Business Wire
Mon Nov 7, 2022
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that positive preclinical data from four new pipeline programs will be featured...
Adicet Bio Reports ASH Abstract Data from Ongoing ADI-001 Phase 1 Trial in Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)
Business Wire - Thu Nov 3, 2022
Business Wire
Thu Nov 3, 2022
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that an abstract detailing updated safety and efficacy data from the Company’s...
Adicet Bio to Present at the 2022 Jefferies London Healthcare Conference
Business Wire - Tue Nov 1, 2022
Business Wire
Tue Nov 1, 2022
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that Chen Schor, President and Chief Executive Officer, will present at the 2022...
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Business Wire - Mon Oct 31, 2022
Business Wire
Mon Oct 31, 2022
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced it granted inducement awards on October 31, 2022 (the “Grant Date”) under...
Adicet Bio to Present Preclinical Data from Allogeneic Gamma Delta T Cell Pipeline Programs at The Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
Business Wire - Wed Oct 5, 2022
Business Wire
Wed Oct 5, 2022
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first in class, allogeneic chimeric antigen receptor (CAR) and adaptor (CAd) gamma delta T cell therapies today announced four preclinical abstract...
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Business Wire - Fri Sep 30, 2022
Business Wire
Fri Sep 30, 2022
Adicet Bio, Inc. (Nasdaq: ACET), a clinical-stage biotechnology company discovering and developing allogeneic gamma delta CAR T cell therapies for cancer, today announced it granted inducement awards on September 30, 2022 (the “Grant Date”) under...
Adicet Bio to Present at Upcoming Investor Conferences
Business Wire - Wed Sep 7, 2022
Business Wire
Wed Sep 7, 2022
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapies for cancer, today announced that company management will...
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Business Wire - Wed Aug 31, 2022
Business Wire
Wed Aug 31, 2022
Adicet Bio, Inc. (Nasdaq: ACET), a clinical-stage biotechnology company discovering and developing allogeneic gamma delta CAR T cell therapies for cancer, today announced it granted inducement awards on August 31, 2022 (the “Grant Date”) under...
Adicet Reports Second Quarter 2022 Financial Results and Provides Business Updates
Business Wire - Wed Aug 10, 2022
Business Wire
Wed Aug 10, 2022
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta CAR T cell therapies for cancer, today reported financial results and operational highlights for the second...
Adicet Bio to Present at Upcoming Investor Conferences
Business Wire - Mon Aug 1, 2022
Business Wire
Mon Aug 1, 2022
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapies for cancer, today announced that company management will...